Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data

被引:38
作者
Earley, Willie [1 ]
Guo, Hua [1 ]
Daniel, David [2 ]
Nasrallah, Henry [3 ]
Durgam, Suresh [1 ]
Zhong, Yan [1 ]
Patel, Mehul [1 ]
Barabassy, Agota [4 ]
Szatmari, Balazs [4 ]
Nemeth, Gyorgy [4 ]
机构
[1] Allergan Plc, Madison, NJ USA
[2] George Washington Univ, Bracket Global LLC, Washington, DC USA
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Gedeon Richter Plc, Budapest, Hungary
关键词
Cariprazine; Schizophrenia; Negative symptoms; Aripiprazole; Risperidone; DOPAMINE D-3 RECEPTOR; ANTIPSYCHOTIC-LIKE ACTIVITY; BEHAVIORAL CHARACTERIZATION; ACUTE EXACERBATION; PARTIAL AGONIST; RATING-SCALE; DOUBLE-BLIND; ANTAGONISM; RISPERIDONE; MEMORY;
D O I
10.1016/j.schres.2018.08.020
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Although currently approved antipsychotics exert efficacy on positive symptoms of schizophrenia, treatments for negative symptoms remain a major unmet need. Post hoc analyses were used to investigate the possible efficacy of cariprazine in patients with moderate/severe negative symptoms of schizophrenia and no predominance of positive symptoms. Data were pooled from 2 randomized, double-blind, placebo- and active-controlled cariprazine studies in patients with acute schizophrenia (NCT00694707, NCT01104766). Analyses included data from a subset of patients with a Positive and Negative Syndrome Scale factor score for negative symptoms (PANSS-FSNS) >= 24, PANSS factor score for positive symptoms (PANSS-FSPS) <= 19, and scores of >= 4 on >= 2 of 3 PANSS items (blunted affect [N1], passive/apathetic social withdrawal [N4], lack of spontaneity/flow of conversation [N6]). Changes from baseline to week 6 in PANSS-FSNS were evaluated in the following treatment groups: placebo (n = 79), cariprazine 1.5-3 (n = 94) and 4.5-6 mg/d (n = 66), risperidone 4 mg/d (n= 34), or aripiprazole 10 mg/d (n = 44). Significant differences were observed versus placebo for cariprazine (1.5-3 mg/d, P = .0179; 4.5-6 mg/d, P = .0002) and risperidone (P = .0149), but not aripiprazole (P = .3265), and versus aripiprazole for cariprazine 4.5-6 mg/d (P = .0197). After adjusting for positive symptom changes, differences versus placebo remained statistically significant for cariprazine (1.5-3 mg/d, P = .0322; 4.5-6 mg/d, P = .0038) but not for risperidone (P = .2204). PANSS-FSNS response (>= 20% reduction from baseline) rates were significantly higher with cariprazine (1.5-3 mg/d = 54.3%, P = .0194; 4.5-6 mg/d = 69.7%, P = .0001) than placebo (35.4%). In patients with acute schizophrenia and moderate/severe negative symptoms, cariprazine was associated with significantly greater improvement in negative symptoms compared with placebo and aripiprazole, warranting further exploration of the efficacy of cariprazine on negative symptoms. (C) 2018 The Authors. Published by Elsevier B.V.
引用
收藏
页码:282 / 288
页数:7
相关论文
共 44 条
[1]  
Abilify, 2016, PACK INS
[2]  
[Anonymous], 1976, CLIN GLOBAL IMPRESSI, DOI DOI 10.1016/J.BIOPHA.2016.11.034
[3]  
[Anonymous], 1976, CGI clinical global impressions
[4]  
APA, 2000, DIAGN STAT MAN MENT, P2000
[5]  
ARETHA CW, 1995, J PHARMACOL EXP THER, V274, P609
[6]   A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].
BARNES, TRE .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676
[7]   Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial [J].
Durgam, Suresh ;
Cutler, Andrew J. ;
Lu, Kaifeng ;
Migliore, Raffaele ;
Ruth, Adam ;
Laszlovszky, Istvan ;
Nemeth, Gyoergy ;
Meltzer, Herbert Y. .
JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (12) :E1574-+
[8]   An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial [J].
Durgam, Suresh ;
Starace, Anju ;
Li, Dayong ;
Migliore, Raffaele ;
Ruth, Adam ;
Nemeth, Gyoergy ;
Laszlovszky, Istvan .
SCHIZOPHRENIA RESEARCH, 2014, 152 (2-3) :450-457
[9]   Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model [J].
Duric, Vanja ;
Banasr, Mounira ;
Franklin, Tina ;
Lepack, Ashley ;
Adham, Nika ;
Kiss, Bela ;
Gyertyan, Istvan ;
Duman, Ronald S. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (10) :788-796
[10]  
Girgis R. R., 2017, 56 ANN M AM COLL NEU